Pierre Fabre S.a.

Pierre Fabre Medicament

Lucien D D'Hinterland

Gerard Normier

Anne-Marie Pinel

Jacques Durand

Alain Le Pape

Hubert Serre

The present invention relates to an aerosol composition containing a carrier agent capable of recognizing and binding to inflammatory and tumor foci mobilizing macrophages in their immediate environment, and an aerosol substrate, characterized in that the said carrier agent consists of a polysaccharide compound selected from the compound D 25, extracted from the membrane proteoglycans of the bacterium Klebsiella pneumoniae and having a molecular weight of 30.+-.0.10 Kd, and the compound oxidized D 25 in which the galactofuranoser residue (Gal.sub.f) of the linear polysaccharide chain of D 25 has been converted to arabinose, and their amide, ester or ether type derivatives, as well as their quaternary ammonium derivatives and salts, and also the derivatives obtained by grafting of phosphatides.

Method for detecting and locating inflammatory or tumor foci in a

The present invention relates to a polysaccharide derivative, which is a derivative of D.25 in which the galactofuranose (Gal.sub.f) residues of the linear polysaccharide chain have been converted at least partly to arabinose. It also relates to the process for its preparation, to its use as an immunostimulant, and to pharmaceutical compositions containing the derivative.

Derivative of D.25, process for its preparation, its use as an

The present invention relates to a vaccinal complex containing a specific antigen. This is a vaccinal complex characterized in that it is composed of bacterial ribosomal RNA or fragments of bacterial ribosomal RNA on which are coupled from 1 to 5% by weight of a specific antigen of bacterial serotype. This complex may be used as a vaccine.

Vaccinal complex containing a specific antigen and vaccine containing it

This invention relates to a process for the preparation of purified bacterial membranal proteoglycans. The process comprises at least one step in which crude proteoglycans are treated in aqueous medium with a base or a hypobromite, followed by elimination of the excess reactant and the insoluble residue, the purified proteoglycans being present in aqueous solution. The thus obtained purified proteoglycans may be used as immunity adjuvants in vaccines without causing side-effects such as pyrogenic reactions.

Preparations of purified bacterial membranal proteoglycans

Vaccines which comprise in association the ribosomal fraction extracted from the bacterias against which a protection is wanted, and the peptidoglycanes extracted from the membranes of at least one of the bacteria previously used.

Growing community of inventors

Castres, France

Lucien D D'Hinterland